17 results about "Lipid absorption" patented technology

To reveal the health benefits of Ecklonia kurome and to provide compositions that can be used in foods and the like.SOLUTION: Provided is a composition for lipase activity inhibition, lipid absorption inhibition, stool slippage improvement, or intestinal regulation, which contains an effective amount of the water extract of Ecklonia kurome. Provided is a method for producing the water extract or processed product of Ecklonia kurome, including the following step: (1) extracting Ecklonia kurome with hot water at 50-80°C for 1-5 hours.SELECTED DRAWING: Figure 1

The invention discloses an application of ganoderic acid A in preparation of a product for preventing and / or treating a non-alcoholic fatty liver disease. The ganoderic acid A can regulate bile acid reabsorption of C57BL / 6J mice induced by high fat diet and reduce absorption of triglyceride and cholesterol. The ganoderic acid A can also enhance expression of a key enzyme cholesterol 7alpha-hydroxylase gene for liver cholesterol decomposition, so that liver cholesterol is promoted to be converted into bile acid, and accumulation of liver cholesterol is relieved. The ganoderic acid A has remarkable prevention and improvement effects on the non-alcoholic fatty liver disease induced by high fat diet by regulating bile acid metabolism, inhibiting lipid absorption and relieving liver lipid accumulation. Therefore, the ganoderic acid A can be used as a health-care product, a functional product or a medicine for preventing and treating the non-alcoholic fatty liver disease.

Disclosed herein, are compositions comprising bacterial strains from Clostridia or Bacilli, and methods of treating obesity, metabolic syndrome, inflammatory bowel disease, as well as reducing weight gain, inhibiting lipid absorption in the small intestine and downregulating CD36 in the liver or small intestine by administering the compositions to a subject.

Use of ganoderic acid A in the preparation of a product for preventing and / or treating non-alcoholic fatty liver disease. Ganoderic acid A can regulate bile acid reabsorption in C57BL / 6J mice induced by a high-fat diet, and reduce the absorption of triglycerides and cholesterol. Ganoderic acid A can also enhance the expression of the gene of cholesterol 7α-hydroxylase, a key enzyme for liver cholesterol decomposition, thereby promoting the conversion of liver cholesterol into bile acid, and alleviating the accumulation of liver cholesterol. Ganoderic acid A has a significant preventive and ameliorative effect on non-alcoholic fatty liver disease induced by a high-fat diet by means of regulating bile acid metabolism, inhibiting lipid absorption, and reducing liver lipid accumulation. Therefore, ganoderic acid A can be used as a health care product, a functional product, or a drug for preventing and treating non-alcoholic fatty liver disease.

To provide a lipid absorption promoter.SOLUTION: A lipid absorption promoter composed of 2'-fucosyllactose.SELECTED DRAWING: Figure 1

The application provides a method for regulating lipid absorption, a composition and application thereof. The present inventors have been committed to the research on the correlation between diet and metabolism, and found in the previous research that compared with before diet restriction, re-feeding after diet restriction can significantly increase the body fat content. Further research shows that the composition of intestinal flora during normal diet after diet restriction changes significantly, and the proportion of lactobacillus increases significantly; high-protein diet after diet restriction can significantly inhibit the increase of the proportion of small intestinal lactobacillus, and the diversity of flora is significantly increased. Clearing the intestinal flora can effectively inhibit the increase of body fat caused by re-feeding after diet restriction. The present inventors have also found that a five-compound combination of a specific lactobacillus strain can significantly increase lipid absorption and fatty acid uptake of white adipose tissue.

Certain intestinal or commensal bacteria (produced naturally or in vitro) induce Th17 cells, leading to production of IL-17, reducing lipid absorption, and thereby counteracting metabolic syndrome, obesity, and associated morbidities, such as type-2 diabetes, cardiovascular disease, and NASH / NAFLD. Administration of those bacteria, or of Th17 cells induced by those bacteria, to a subject helps counteract metabolic syndrome and associated morbidities. Antagonists of intestinal CD36 or molecules decreasing intestinal CD36, e.g., IL-17, may also be used to reduce lipid absorption. Depletion of Faecalibacterium rodentium or members of the Erysipelotrichaceae family in the subject may provide a similar result. ILC3 or IL-22 blockade (alone or combined with Th17 cell administration or induction if not already present in the subject), may further provide a similar result, protecting against metabolic disease.

The invention provides electrolyte-containing coffee as well as a preparation method and application thereof, and belongs to the technical field of coffee beverages. According to the invention, only components such as coffee concentrate, instant coffee powder, erythritol, potassium citrate, sodium citrate, vitamin B3, vitamin B6, synthetic vitamin E acetate dry powder, grapefruit concentrated juice, purified water and the like are adopted, and preservatives or additives such as dipotassium phosphate and the like are not used. The black coffee liquid, the electrolyte and the grapefruit concentrated juice are effectively combined, so that absorption of intestinal tracts to lipid can be inhibited, generation of stimulated bile acid is reduced, the risk of gastric mucosa damage is reduced, the content of triglyceride and cholesterol in excrement is increased, accumulation of fat in bodies is reduced, and weight rise of high-fat diet mice can be effectively relieved.

The present application belongs to the field of food oil and fat, and particularly relates to an oil and fat composition, a preparation method and use thereof. The oil and fat composition comprises sterol laurate and modified palm oil, wherein the mass ratio of the sterol laurate and the modified palm oil is (0.5-3):100. The sterol is subjected to esterification with lauric acid under vacuum to obtain a sterol laurate esterification product; the enzyme-modified palm oil is stirred and mixed with the sterol laurate esterification product to obtain the oil and fat additive suitable for poultry daily ration. The present application firstly utilizes the oil and fat composition prepared by compounding the enzyme-modified palm oil and the sterol laurate esterification product as the oil and fat for poultry daily ration. The oil and fat composition reduces the feed-meat ratio of broiler, improves the lipid absorption rate, and improves the absorption of calcium and phosphorus by poultry.

The invention discloses targeted prebiotic plant extraction dietary powder for conditioning hyperlipidemia and a preparation process of the targeted prebiotic plant extraction dietary powder. In the invention, patent strains such as lactobacillus plantarum LP-12, bifidobacterium longum BL-08 and the like in the formula can regulate intestinal flora balance and inhibit activity of liver cholesterol synthesis key enzymes, so that generation of endogenous cholesterol is reduced from the source; natural monacolin K and phytosterol ester in the red yeast rice powder respectively inhibit cholesterol synthesis and competitively block exogenous cholesterol absorption to form a bidirectional regulation mechanism. Meanwhile, the oat beta-glucan forms an adhesive layer in the intestinal tract, so that part of lipid absorption is physically blocked; and prebiotics such as resistant dextrin and fructo-oligosaccharide provide nutrients for probiotics, promote secretion of short-chain fatty acids and further activate lipid metabolism related pathways. The components cooperate with one another to cover the whole chain of cholesterol synthesis, absorption and metabolism, so that the multi-dimensional lipid-lowering effect of'source inhibition-process blocking-metabolic regulation 'is realized.

This invention relates to the pharmaceutical field, specifically to an egg yolk-derived peptide for lowering blood lipids, its preparation method, pharmaceutical composition, and uses. This invention discovers an egg yolk-derived peptide obtained by enzymatic hydrolysis, digestion, separation, and purification of defatted egg yolk powder. Its amino acid sequence is shown in SEQ ID NO.1. This peptide possesses high potential activity for lowering blood lipids. In vitro pancreatic lipase inhibition experiments and hyperlipidemic cell model experiments demonstrate that the egg yolk-derived peptide of this invention can affect lipid absorption and metabolism, thereby alleviating lipid metabolism disorders and lipid accumulation, ultimately reducing TC and TG levels.

The invention discloses a probiotic dietary fiber composite composition for body weight management and a preparation method thereof in the field of functional food. The composition comprises a composite system composed of probiotics, prebiotics, a dietary fiber matrix and two special inorganic modified carriers. The two carriers are respectively a mesoporous silica magnesium-aluminum layered double hydroxide hybrid nano-carrier and a zinc-doped calcium phosphate silica core-shell nano-particle. During preparation, firstly, the probiotics are loaded on the hybrid nano-carrier and protected, then the hybrid nano-carrier, the core-shell nanoparticles, fructo-oligosaccharide and other components are compounded into a gel matrix constructed by cellulose nanofibers and carrageenan together, and a final product is obtained through homogenization and freeze drying. Through the synergistic effect of the two carriers, the targeted survival rate of the probiotics in the intestinal tract is remarkably improved, and the multiple effects of adsorbing grease, delaying glycolipid absorption and adjusting intestinal flora are achieved at the same time, so that safe and effective weight management is achieved.

The invention discloses a compound substitutional tea bag with blood pressure and blood fat reducing functions and a preparation method thereof, and the compound substitutional tea bag is used for synergistically assisting in reducing blood pressure from different mechanisms through the vasodilation effect of gastrodia elata and radix puerariae, the cardiovascular protection effect of chrysanthemum and the diuretic effect of corn stigma; the hawthorn, the semen cassiae, the lotus leaves and the lucid ganoderma are used for regulating and controlling lipid absorption, synthesis and excretion in multiple links, so that the effect of assisting in reducing blood fat is jointly exerted; besides, the flavors of all the raw materials are ingeniously balanced, the sour and refreshing taste of hawthorn, the faint scent of chrysanthemum and the sweet and light taste of corn stigma effectively neutralize the slight bitter taste of semen cassiae and lotus leaves, and due to the fact that gastrodia elata, radix puerariae and lucid ganoderma do not have obvious bad flavors, final tea soup is clear in color and luster, mellow in taste, free of strong bitter taste of traditional Chinese medicine and easy to accept by consumers; the long-term drinking compliance is ensured.

This invention discloses a method for assessing lipid reesterification, belonging to the field of biochemistry. Based on radioisotope-labeled assisted liquid scintillation counting technology, this invention provides a method for evaluating the reesterification of functional lipids. For the reaction of fatty acids with coenzyme A to form acyl-CoA, coenzyme A is labeled with a radioisotope, and the reesterification rate of fatty acids is quantified by calculating the isotope recovery rate in the product. For the reaction of sterols with acyl-CoA to form sterol fatty acid esters, sterols and acyl-CoA are labeled with two different isotopes respectively. The reduction of acyl-CoA in the reactants and the formation of sterol fatty acid esters in the product are characterized by detecting the intensity of the two isotopes simultaneously carried in the product, thus quantifying the reesterification rate of sterols. This invention uses labeled coenzyme A as an evaluator for the metabolic process, precisely locating the lipid metabolic pathway to the esterification reaction involving coenzyme A, eliminating the influence of unknown metabolic pathways.

The invention discloses an application of taurodeoxycholic acid in preparation of a medicine for recovering damaged hematopoietic stem cells, taurodeoxycholic acid TDCA is formed by combining deoxycholic acid Deoxycholic acid, DCA and taurine, belongs to secondary bile acid, contains two hydroxyls 3 alpha and 12 alpha, and is relatively high in hydrophobicity. The TDCA can promote lipid absorption and help to emulsify fat and fat-soluble vitamins. The TDCA is mainly used for anti-inflammation and liver protection, can relieve liver inflammation and fibrosis such as non-alcoholic fatty liver disease and cholestasis through an FXR pathway and can be potentially used for treating inflammatory bowel disease IBD, and it is found that the TDCA can recover the number and functions of hematopoietic cells of mice with hematopoietic damage caused by long-term drinking of high-temperature water besides the functions.

The present application relates to a probiotic and its application in regulating the direction of lipid metabolism. Specifically, the present application relates to the use of the probiotic in the preparation of a medicine or food. The present application also relates to a method for regulating the body weight of a subject, and a method for inhibiting or reducing the absorption of lipids in the gastrointestinal tract of a subject.